Skip to content

Acute Pancreatitis: A Comprehensive Exploration of immune lineages.

Acute Pancreatitis: A Comprehensive Exploration of immune lineages. - APACHE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON46341
Enrollment
80
Registered
2018-07-18
Start date
2018-08-01
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

None listed

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients In order to be eligible to participate in this study, a subject must meet all of the following criteria: Suspected acute biliary, alcoholic or idiopathic pancreatitis At least 2 out of 3 criteria of acute pancreatitis: - Pain in upper abdomen - Serum amylase and/or lipase >3x upper limit of normal (ULN) - Signs of acute pancreatitis on CT or MR * 18 years old Provide informed consent;Healthy volunteers A person is eligible to participate as healthy volunteer if they are considered to be healthy and if their age and gender matches with a patient included in this study.

Exclusion criteria

Exclusion criteria: Use of medications with possible immune-modulating effects (e.g., steroids or recent chemotherapy) Time from onset of abdominal pain to hospital admission >48 hours Established diagnosis of chronic pancreatitis Suspected cholangitis;Healthy volunteers Use of medications with possible immune-modulating effects (e.g., steroids or recent chemotherapy) Current or recent (in the last two weeks) infectious disease (i.e. influenza) Systemic diseases

Design outcomes

Primary

MeasureTime frame
The main study parameters are immune subsets which consist of a clustering of peripheral blood leukocytes.

Secondary

MeasureTime frame
Secondary study parameters include serum urea, CRP, leukocyte counts, mortality, morbidity, days of admission, prognostic scores, medical history, medication, alcohol and drug use.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)